Other Clinical Trial - The Effect of Sitagliptin in Type 2 Diabetes

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Diabetes Mellitus
Diabetes Mellitus Non-insulin-dependent
Diabetes Mellitus, Type 2

See also
Status	Clinical Trial	Phase
Completed	`NCT00642798` - An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)	Phase 1
Suspended	`NCT01925443` - Effects of Low Power Laser Therapy on Muscle Performance Isokinetic Pre-exercise in Individuals With Diabetes Mellitus Type II	N/A
Completed	`NCT06235762` - The Effects of Nutritional Intervention on Health Parameters in Participants With Type 2 Diabetes Mellitus	N/A

See also

Status

Clinical Trial

Phase

Completed

NCT00642798 - An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)

Phase 1

Suspended

NCT01925443 - Effects of Low Power Laser Therapy on Muscle Performance Isokinetic Pre-exercise in Individuals With Diabetes Mellitus Type II

N/A

Completed

NCT06235762 - The Effects of Nutritional Intervention on Health Parameters in Participants With Type 2 Diabetes Mellitus

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT00832624
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Terminated
Phase	Phase 4
Start date	November 2008
Completion date	September 2009

The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms